Studies indicated that inhibition of METTL3 and METTL14 may sensitize cancers, including AML, to chemotherapy.83 Inhibition of METTL3 has also been shown to improve the efficacy of immune therapies, particularly in colorectal cancer and melanoma.86 However, the clinical application of RNA modification enzyme inhibitors faces several challenges, including drug delivery, personalized treatment strategies, and optimization of drug selectivity. The gene discussed is METTL3; the disease is colorectal cancer.